Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tert-butyl 2-cyano-2-methylhydrazinecarboxylate
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
tert-Butyl 2-cyano-2-methylhydrazinecarboxylate is a small molecule organic compound with molecular formula C7H13N3O2 and molecular weight approximately 171.20 g/mol. It acts as a cathepsin K inhibitor, which suggests potential utility in modulating protease activity related to bone resorption or other biological processes involving cathepsin K. The compound is experimental and not approved for clinical use. It has been studied primarily in research contexts rather than as an established pharmaceutical drug.
- Other names
- tert-butyl N-[cyano(methyl)amino]carbamateN′-cyano-N′-methyl(tert-butoxy)carbohydrazideN′-cyano-N′-methyltert-butoxycarbohydrazide
02
Targets
CTSK (Cathepsin K)
Beyond the preview
Go deeper on tert-butyl 2-cyano-2-methylhydrazinecarboxylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tert-butyl 2-cyano-2-methylhydrazinecarboxylate.